LIke ThisLIke ThisLIke This

Ploegh Lab Highlights

March 10, 2017

Transfusing engineered red blood cells to protect against autoimmune disease

Autoimmune disease is usually treated using general immunosuppressants. But this non-targeted therapy leaves the body more susceptible to infection and other life-threatening diseases. Now, scientists at Boston Children’s Hospital, the Massachusetts Institute of Technology (MIT) and the Whitehead Institute for Biomedical Research think they may have found a targeted way to protect the body from autoimmune disease. Their approach, published in Proceedings of the National Academy of Sciences, uses transfusions of engineered red blood cells to re-train the immune system. Early experiments in mice have already shown that the approach can prevent — and even reverse — clinical signs of two autoimmune diseases: a multiple-sclerosis (MS)-like condition and Type 1 diabetes. 

Read More

January 4, 2017

Ross Cheloha was awarded CRI Post-doctoral Fellowship

Congratulations to Ross Cheloha, who has been awarded a post-doctoral fellowship from the Cancer Research Institute (CRI).

Ross Cheloha will investigate how the BCR (B cell receptor) is trafficked within B cells in order to provide means to promote beneficial BCR activity and inhibit detrimental activity. To provide a brief background, B cells help provide immunity against infections and cancer through the action of a protein complex on their surface (B cell receptor, BCR). Abnormal BCR activity can cause B cells to become cancerous or cause autoimmune diseases.

LIke ThisLIke ThisLIke This